Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma

References

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 2. Wagner AD, Syn NLX, Moehler M et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 8(8), CD004064 (2017).
  MedlineGoogle Scholar
• 3. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a Phase III, open-label, randomized controlled trial. Lancet 376(9742), 687–697 (2010).
  Medline CASGoogle Scholar
• 4. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized Phase III trial. Lancet Oncol. 15(11), 1224–1235 (2014).
  Medline CASGoogle Scholar
• 5. Oh DY, Bang YJ. HER2-targeted therapies – a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17(1), 33–48 (2020).
  Medline CASGoogle Scholar
• 6. Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am. J. Cancer Res. 10(4), 1045 (2020).
  MedlineGoogle Scholar
• 7. Van Cutsem E, Bang YJ, Feng-yi F et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastresophageal junction cancer. Gastric Cancer. 18(3), 476–484 (2015).
  Medline CASGoogle Scholar
• 8. Hecht JR, Bang YJ, Qin SK et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastresophageal adenocarcinoma: TRIO-013/LOGiC – a randomized Phase III trial. J. Clin. Oncol. 34(5), 443–451 (2016).
  Medline CASGoogle Scholar
• 9. Tabernero J, Hoff PM, Shen L et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-esophageal junction cancer (JACOB): final analysis of a double-blind, randomized, placebo-controlled Phase III study. Lancet Oncol. 19(10), 1372–1384 (2018).
  Medline CASGoogle Scholar
• 10. Shah MA, Xu R hua, Bang YJ et al. HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2–positive metastatic gastric or gast. J. Clin. Oncol. 35(22), 2558–2567 (2017).
  Medline CASGoogle Scholar
• 11. Janjigian YY, Maron SB, Chatila WK et al. First-line pembrolizumab and trastuzumab in HER2-positive esophageal, gastric, or gastro-esophageal junction cancer: an open-label, single-arm, Phase II trial. Lancet Oncol. 2(20), 1–11 (2020).
  Google Scholar
• 12. Satoh T, Doi T, Ohtsu A et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, Phase III study. J. Clin. Oncol. 32(19), 2039–2049 (2014).
  Medline CASGoogle Scholar
• 13. Thuss-Patience PC, Shah MA, Ohtsu A et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GATSBY): an international randomized, open-label, adaptive, Phase II/III study. Lancet Oncol. 18(5), 640–653 (2017).
  Medline CASGoogle Scholar
• 14. Makiyama A, Sukawa Y, Kashiwada T et al. Randomized, Phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastresophageal junction cancer: WJOG7112G (T-ACT Study). J. Clin. Oncol. JCO.19.03077 38(17), 1919–1927 (2020).
  Medline CASGoogle Scholar
• 15. Park H, Uronis H, Kang Y-K et al. Determinants of response of HER2+ gastric cancer (GC) vs gastresophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T). Ann. Oncol. 30, v485 (2019).
  Google Scholar
• 16. Shitara K, Bang Y-J, Iwasa S et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastresophageal junction (GEJ) adenocarcinoma: a randomized, Phase II, multicenter, open-label study (DESTINY-Gastric01). J. Clin. Oncol. 38(Suppl. 15), 4513 (2020).
  Google Scholar
• 17. Yamaguchi K, Bang Y-J, Iwasa S et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastresophageal junction (GEJ) adenocarcinoma: results of the exploratory cohorts in the Phase II, multicenter, open-label DESTINY-Gastric01 study. Ann. Oncol. 31, S899–S900 (2020).
  Google Scholar
• 18. Bartley AN, Washington MK, Ventura CB et al. HER2 testing and clinical decision making in gastresophageal adenocarcinoma guideline from the College of American Pathologists, American Society for clinical Pathology, and American Society of Clinical Oncology. Am. J. Clin. Pathol. 146(6), 647–669 (2016).
  MedlineGoogle Scholar
• 19. Lee HE, Park KU, Yoo SB et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur. J. Cancer 49(6), 1448–1457 (2013).
  Medline CASGoogle Scholar
• 20. Saeki H, Oki E, Kashiwada T et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur. J. Cancer 105, 41–49 (2018).
  Medline CASGoogle Scholar
• 21. Pietrantonio F, Fuca G, Morano F et al. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: The AMNESIA case-control study. Clin. Cancer Res. 24(5), 1082–1089 (2018).
  Medline CASGoogle Scholar
• 22. Gambardella V, Fleitas T, Tarazona N et al. Towards precision oncology for HER2 blockade in gastresophageal adenocarcinoma. Ann. Oncol. 30(8), 1254–1264 (2019).
  Medline CASGoogle Scholar
• 23. Ogitani Y, Aida T, Hagihara K et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22(20), 5097–5108 (2016).
  Medline CASGoogle Scholar
• 24. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107(7), 1039–1046 (2016).
  Medline CASGoogle Scholar
• 25. Shitara K, Iwata H, Takahashi S et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, Phase I study. Lancet Oncol. 20(6), 827–836 (2019).
  Medline CASGoogle Scholar
• 26. Shitara K, Bang Y-J, Iwasa S et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419–2430 (2020).
  Medline CASGoogle Scholar
• 27. Doi T, Shitara K, Naito Y et al. Safety, pharmacokinetics, and antitumor activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-esophageal tumors: a Phase I dose-escalation study. Lancet Oncol. 18(11), 1512–1522 (2017).
  Medline CASGoogle Scholar
• 28. Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol. Cancer Ther. 17(7), 1494–1503 (2018).
  Medline CASGoogle Scholar
• 29. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94(2), 259–267 (2006).
  Medline CASGoogle Scholar
• 30. Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108(17), 7142–7147 (2011).
  Medline CASGoogle Scholar
• 31. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer. 12(4), 237–251 (2012).
  Medline CASGoogle Scholar
• 32. Janjigian YY, Maron SB, Chatila WK et al. First-line pembrolizumab and trastuzumab in HER2-positive esophageal, gastric, or gastro-esophageal junction cancer: an open-label, single-arm, Phase II trial. Lancet Oncol. 2(20), 1–11 (2020).
  Google Scholar
• 33. Bang YJ, Giaccone G, Im SA et al. First-in-human Phase I study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann. Oncol. 28(4), 855–861 (2017).
  Medline CASGoogle Scholar
• 34. Park H, Uronis H, Kang Y-K et al. Determinants of response of HER2+ gastric cancer (GC) vs gastresophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T). Ann. Oncol. 30, v485 (2019).
  Google Scholar
• 35. Brief NIN. ZW25 effective in HER2-positive cancers. Cancer Discov. 9(1), 8 (2019).
  Google Scholar
• 36. Meric-Bernstam F, Beeram M, Mayordomo JI et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. J. Clin. Oncol. 36(Suppl. 15), 2500 (2018).
  Google Scholar
• 37. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10(2), 116–129 (2010).
  Medline CASGoogle Scholar
• 38. Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17(5), 318–332 (2017).
  Medline CASGoogle Scholar
• 39. Deng N, Goh LK, Wang H et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61(5), 673–684 (2012).
  Medline CASGoogle Scholar
• 40. Liu YJ, Shen D, Yin X et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br. J. Cancer 110(5), 1169–1178 (2014).
  Medline CASGoogle Scholar
• 41. Kunii K, Davis L, Gorenstein J et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68(7), 2340–2348 (2008).
  Medline CASGoogle Scholar
• 42. Matsumoto K, Arao T, Hamaguchi T et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br. J. Cancer 106(4), 727–732 (2012).
  Medline CASGoogle Scholar
• 43. Jung EJ, Jung EJ, Min SY, Kim MA, Kim WH. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum. Pathol. 43(10), 1559–1566 (2012).
  Medline CASGoogle Scholar
• 44. Xie L, Su X, Zhang L et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19(9), 2572–2583 (2013).
  Medline CASGoogle Scholar
• 45. Van Cutsem E, Bang YJ, Mansoor W et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann. Oncol. 28(6), 1316–1324 (2017).
  Medline CASGoogle Scholar
• 46. Smyth EC, Turner NC, Pearson A et al. Phase II study of AZD4547 in FGFR amplified tumors: gastresophageal cancer (GC) cohort pharmacodynamic and biomarker results. J. Clin. Oncol. 34(Suppl. 4), 154 (2016).
  Google Scholar
• 47. Pearson A, Smyth E, Babina IS et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 6(8), 838–851 (2016).
  Medline CASGoogle Scholar
• 48. Kuboki Y, Matsubara N, Bando H et al. First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. Ann. Oncol. 28(Suppl. 5), v122–v141 (2017).
  Google Scholar
• 49. Catenacci DVT, Rha SY, Bang Y-J et al. Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer. J. Clin. Oncol. 35(Suppl. 15), 4067 (2017).
  Google Scholar
• 50. Tejani MA, Cheung E, Eisenberg PD et al. Phase I results from the Phase I/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC). J. Clin. Oncol. 37(Suppl. 4), 91 (2019).
  Google Scholar
• 51. Catenacci DVT, Tesfaye A, Tejani M et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastresophageal cancer: FIGHT Phase III study design. Futur. Oncol. 15(18), 2073–2082 (2019).
  CASGoogle Scholar
• 52. McSheehy P, Bachmann F, Forster-Gross N et al. The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR. J. Clin. Oncol. 38(Suppl. 4), 421 (2020).
  Google Scholar
• 53. Hall TG, Yu Y, Eathiraj S et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS ONE 11(9), 3–5 (2016).
  Google Scholar
• 54. Peranzoni E, Lemoine J, Vimeux L et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proc. Natl Acad. Sci. USA 115(17), E4041–E4050 (2018).
  Medline CASGoogle Scholar
• 55. Zhu Y, Knolhoff BL, Meyer MA et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74(18), 5057–5069 (2014).
  Medline CASGoogle Scholar
• 56. Basilea. Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASCO Gastrointestinal Cancers Symposium. (2020). https://www.basilea.com/news/news/basilea-reports-activity-of-derazantinib-in-preclinical-models-of-gastric-cancer-at-asco-gastrointestinal-cancers-symposium?type=1546938654
  Google Scholar
• 57. Mori M, Sawada N, Kokai Y, Satoh M. Role of tight junctions in the occurrence of cancer invasion and metastasis. Med. Electron Microsc. 32(4), 193–198 (1999).
  MedlineGoogle Scholar
• 58. Sahin U, Koslowski M, Dhaene K et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14(23), 7624–7634 (2008).
  Medline CASGoogle Scholar
• 59. Bass AJ, Thorsson V, Shmulevich I et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202–209 (2014).
  MedlineGoogle Scholar
• 60. Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J. Hematol. Oncol. 10(1), 1–5 (2017).
  MedlineGoogle Scholar
• 61. Kreuzberg M, Mitnacht-Kraus R, Sahin U, Türeci Ö. Preclinical characterization of IMAB362-VCMMAE, an anti-CLDN18.2 antibody–drug conjugate. Ann. Oncol. 28(Suppl. 5), v122–v141 (2017).
  Google Scholar
• 62. Türeci O, Sahin U, Schulze-Bergkamen H et al. A multicenter, Phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann. Oncol. 30(9), 1487–1495 (2019).
  MedlineGoogle Scholar
• 63. Sahin U, Türeci, Manikhas G et al. FAST: a randomized Phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-esophageal adenocarcinoma. Ann. Oncol. 32(5), 609–619 (2021).
  Medline CASGoogle Scholar
• 64. Shah MA, Ajani JA, Al-Batran S-E et al. Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2-advanced or metastatic gastric or gastresophageal junction adenocarcinoma: GLOW. J. Clin. Oncol. 38(Suppl. 15), TPS4648–TPS4648 (2020).
  Google Scholar
• 65. Iveson T, Donehower RC, Davidenko I et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or esophagogastric junction adenocarcinoma: an open-label, dose de-escalation Phase Ib study and a double-blind, randomized Phase II study. Lancet Oncol. 15(9), 1007–1018 (2014).
  Medline CASGoogle Scholar
• 66. Catenacci DVT, Tebbutt NC, Davidenko I et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-esophageal junction cancer (RILOMET-1): a randomized, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 18(11), 1467–1482 (2017).
  Medline CASGoogle Scholar
• 67. Doi T, Kang Y-K, Muro K, Jiang Y, Jain RK, Lizambri R. A Phase III, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastresophageal junction (G). J. Clin. Oncol. 33(Suppl. 3), TPS226–TPS226 (2015).
  Google Scholar
• 68. Shah MA, Bang YJ, Lordick F et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastresophageal adenocarcinoma: the METGastric randomized clinical trial. JAMA Oncol. 3(5), 620–627 (2017).
  MedlineGoogle Scholar
• 69. Zang DY, Sohn S-H, Kim B et al. Tepotinib inhibits the epithelial-mesenchymal transition and tumor growth of gastric cancers via increasing GSK3β, ECAD, MUC5AC, and MUC6. J. Clin. Oncol. 38 (Suppl. 15), e16562–e16562 (2020).
  Google Scholar
• 70. Li J, Guo Y, Xue J et al. First-in-human (FIH) Phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor. J. Clin. Oncol. 38(Suppl. 15), e16126–e16126 (2020).
  Google Scholar
• 71. Kim HS, Kim MA, Hodgson D et al. Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients. Pathobiology 80(3), 127–137 (2013).
  Medline CASGoogle Scholar
• 72. Bang YJ, Im SA, Lee KW et al. Randomized, double-blind Phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J. Clin. Oncol. 33(33), 3858–3865 (2015).
  Medline CASGoogle Scholar
• 73. Bang YJ, Xu RH, Chin K et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomized, placebo-controlled, Phase III trial. Lancet Oncol. 18(12), 1637–1651 (2017).
  Medline CASGoogle Scholar
• 74. Smyth E. Missing a GOLDen opportunity in gastric cancer. Lancet Oncol. 18, 1561–1563 (2017).
  MedlineGoogle Scholar
• 75. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 500(7463), 415–421 (2013).
  Medline CASGoogle Scholar
• 76. Alexandrov LB, Nik-Zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat. Commun. 6, 1–7 (2015).
  Google Scholar
• 77. Secrier M, Li X, De Silva N et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat. Genet. 48(10), 1131–1141 (2016).
  Medline CASGoogle Scholar
• 78. Mamdani H, Mehta R, Fountzilas C, Radovich M, Perkins S, Jalal SI. A Phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma: a big ten cancer research consortium study. J. Clin. Oncol. 38(Suppl.4), TPS472–TPS472 (2020).
  Google Scholar
• 79. Moehler M, Shitara K, Garrido M et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastresophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann. Oncol. 31, S1191 (2020).
  Google Scholar
• 80. Boku N, Ryu MH, Oh D-Y et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastresophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Ann. Oncol. 31, S1192 (2020).
  Google Scholar
• 81. Kato K, Sun J-M, Shah MA et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the Phase III KEYNOTE-590 study. Ann. Oncol. 31, S1192–S1193 (2020).
  Google Scholar
• 82. Tabernero J, Van Cutsem E, Bang Y-J et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastresophageal junction (G/GEJ) adenocarcinoma: the Phase III KEYNOTE-062 study. J. Clin. Oncol. 37(Suppl. 18), LBA4007–LBA4007 (2019).
  Google Scholar
• 83. Wang F, Wei XL, Wang FH et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in Phase Ib/II clinical trial NCT02915432. Ann. Oncol. 30(9), 1479–1486 (2019).
  Medline CASGoogle Scholar
• 84. Moehler MH, Dvorkin M, Ozguroglu M et al. Results of the JAVELIN Gastric 100 Phase III trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2- advanced gastric or gastresophageal junction cancer (GC/GEJC). J. Clin. Oncol. 39(9), 966–977 (2020).
  MedlineGoogle Scholar
• 85. Shitara K, Özgüroğlu M, Bang YJ et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-esophageal junction cancer (KEYNOTE-061): a randomized, open-label, controlled, Phase III trial. Lancet 392(10142), 123–133 (2018).
  Medline CASGoogle Scholar
• 86. Metges J, François E, Shah M et al. The Phase III KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Ann. Oncol. 30(July), iv130 (2019).
  Google Scholar
• 87. Kelly RJ, Lee J, Bang YJ et al. Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastresophageal junction adenocarcinoma. Clin. Cancer Res. 26(4), 846–854 (2020).
  Medline CASGoogle Scholar
• 88. Kang YK, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomized, double-blind, placebo-controlled, Phase III trial. Lancet 390(10111), 2461–2471 (2017).
  Medline CASGoogle Scholar
• 89. Fuchs CS, Doi T, Jang RW et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastresophageal junction cancer: Phase II clinical KEYNOTE-059 trial. JAMA Oncol. 4(5), 1–8 (2018).
  MedlineGoogle Scholar
• 90. Bang YJ, Yañez Ruiz E, Van Cutsem E et al. Phase III, randomized trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-esophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann. Oncol. 29(10), 2052–2060 (2018).
  MedlineGoogle Scholar
• 91. Janjigian YY, Bendell J, Calvo E et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J. Clin. Oncol. 36(28), 2836–2844 (2018).
  Medline CASGoogle Scholar
• 92. Muro K, Chung HC, Shankaran V et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicenter, open-label, Phase Ib trial. Lancet Oncol. 17(6), 717–726 (2016).
  Medline CASGoogle Scholar
• 93. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
  Medline CASGoogle Scholar
• 94. Amonkar M, Lorenzi M, Zhang J, Mehta S, Liaw K-L. Structured literature review (SLR) and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in gastric, colorectal, and esophageal cancers. J. Clin. Oncol. 37(Suppl. 15), e15074–e15074 (2019).
  Google Scholar
• 95. Kim ST, Cristescu R, Bass AJ et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 24(9), 1449–1458 (2018).
  Medline CASGoogle Scholar
• 96. Kulangara K, Zhang N, Corigliano E et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch. Pathol. Lab. Med. 143(3), 330–337 (2019).
  Medline CASGoogle Scholar
• 97. Fuchs CS, Özgüroğlu M, Bang Y-J et al. Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastresophageal junction cancer (GC): update from the Phase III KEYNOTE-061 trial. J. Clin. Oncol. 38(Suppl. 15), 4503 (2020).
  Google Scholar
• 98. Wainberg ZA, Fuchs CS, Tabernero J et al. Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the Phase II KEYNOTE-059 (cohort 1) and Phase III KEYNOTE-061 and KEYNOTE-062 studies. J. Clin. Oncol. 38(Suppl. 4), 427 (2020).
  Google Scholar
• 99. Hagi T, Kurokawa Y, Kawabata R et al. Multicenter biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br. J. Cancer 123(6), 965–972 (2020).
  Medline CASGoogle Scholar
• 100. Kulangara K, Zhang N, Corigliano E et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch. Pathol. Lab. Med. 143(3), 330–337 (2019).
  Medline CASGoogle Scholar
• 101. Krigsfeld GS, Prince EA, Pratt J et al. Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumor types. J. Clin. Pathol. 73(10), 656–664 (2020).
  Medline CASGoogle Scholar
• 102. Zhou KI, Peterson B, Serritella A, Reizine N, Wang Y, Catenacci DVT. Evaluation of spatiotemporal heterogeneity of tumor mutational burden (TMB) in gastresophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy. J. Clin. Oncol. 38(Suppl. 15), 4546–4546 (2020).
  Google Scholar
• 103. Bass AJ, Thorsson V, Shmulevich I et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517), 202–209 (2014).
  MedlineGoogle Scholar
• 104. Janjigian YY, Sanchez-Vega F, Jonsson P et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8(1), 49–58 (2018).
  Medline CASGoogle Scholar
• 105. Ayers M, Lunceford J, Nebozhyn M et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127(8), 2930–2940 (2017).
  MedlineGoogle Scholar
• 106. Higgs BW, Morehouse CA, Streicher K et al. Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes in patients with non–small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin. Cancer Res. 24(16), 3857–3866 (2018).
  Medline CASGoogle Scholar
• 107. Lei M, Siemers N, Pandya D et al. Analyses of PD-L1 and inflammatory gene expressionassociation with efficacy of nivolumab + ipilimumab ingastric cancer/gastroesophageal junction cancer. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-20-2790 (2021) (Epub ahead of print).
  Google Scholar
• 108. Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21(5), 449–456 (2015).
  Medline CASGoogle Scholar
• 109. Greally M, Chou JF, Chatila WK et al. Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer. Clin. Cancer Res. 25(20), 6160–6169 (2019).
  Medline CASGoogle Scholar
• 110. Samstein RM, Lee CH, Shoushtari AN et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202–206 (2019).
  Medline CASGoogle Scholar
• 111. Goodman AM, Kato S, Bazhenova L et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16(11), 2598–2608 (2017).
  Medline CASGoogle Scholar
• 112. Campesato LF, Barroso-Sousa R, Jimenez L et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget 6(33), 34221–34227 (2015).
  MedlineGoogle Scholar
• 113. Marabelle A, Fakih MG, Lopez J et al. Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158. Ann. Oncol. 30, v477–v478 (2019).
  Google Scholar
• 114. Fuchs CS, Özgüroğlu M, Bang Y-J et al. The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061. J. Clin. Oncol. 38(Suppl. 15), 4512 (2020).
  Google Scholar
• 115. Shitara K, Özgüroğlu M, Bang Y-J et al. The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061. J. Clin. Oncol. 38(Suppl. 15), 4537 (2020).
  Google Scholar
• 116. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960–1964 (2006).
  Medline CASGoogle Scholar
• 117. Solinas C, Pusole G, Demurtas L et al. Tumor infiltrating lymphocytes in gastrointestinal tumors: controversies and future clinical implications. Crit. Rev. Oncol. Hematol. 110, 106–116 (2017).
  MedlineGoogle Scholar
• 118. Challoner BR, von Loga K, Woolston A et al. Computational image analysis of T-cell infiltrates in resectable gastric cancer: association with survival and molecular subtypes. JNCI J. Natl Cancer Inst. 113(1), 88–98 (2020).
  Google Scholar
• 119. Wang M, Huang YK, Kong JCH et al. High-dimensional analyses reveal a distinct role of T-cell subsets in the immune microenvironment of gastric cancer. Clin. Transl. Immunol. 9(5), e1127 (2020).
  Medline CASGoogle Scholar
• 120. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 541(7637), 321–330 (2017).
  Medline CASGoogle Scholar
• 121. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563–567 (2014).
  Medline CASGoogle Scholar
• 122. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568–571 (2014).
  Medline CASGoogle Scholar
• 123. Kim T, Lee D, Oh D et al. The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry. Ann. Oncol. 30(October), v253 (2019).
  Google Scholar
• 124. Cho J, Chang YH, Heo YJ et al. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open 3(3), e000326 (2018).
  MedlineGoogle Scholar
• 125. Giampieri R, Maccaroni E, Mandolesi A et al. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer. 20(1), 156–163 (2017).
  Medline CASGoogle Scholar
• 126. Lauren P. The two main histological types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31–49 (1965).
  Medline CASGoogle Scholar
• 127. Tae Kim S, Lee J, Hong M et al. Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget 8(39), 66305–66315 (2017).
  MedlineGoogle Scholar
• 128. Lee J, Kim ST, Kim K et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the viktory umbrella trial. Cancer Discov. 9(10), 1388–1405 (2019).
  Medline CASGoogle Scholar
• 129. Catenacci DVT, Peterson B, Chase L et al. Personalized antibodies for gastresophageal adenocarcinoma (PANGEA): secondary and final primary efficacy analyses. J. Clin. Oncol. 38(Suppl. 15), 4561 (2020).
  Google Scholar
• 130. Pectasides E, Stachler MD, Derks S et al. Genomic heterogeneity as a barrier to precision medicine in gastresophageal adenocarcinoma. Cancer Discov. 8(1), 37–48 (2018).
  Medline CASGoogle Scholar
• 131. Davidson M, Barber LJ, Woolston A et al. Detecting and tracking circulating tumor DNA copy number profiles during first line chemotherapy in esophagogastric adenocarcinoma. Cancers (Basel). 11(5), 736 (2019).
  CASGoogle Scholar
• 132. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomized, open-label Phase III trial. Lancet Oncol. 14(6), 490–499 (2013).
  Medline CASGoogle Scholar
• 133. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced esophagogastric cancer (REAL3): a randomized, open-label Phase III trial. Lancet Oncol. 14(6), 481–489 (2013).
  Medline CASGoogle Scholar
• 134. Dutton SJ, Ferry DR, Blazeby JM et al. Gefitinib for esophageal cancer progressing after chemotherapy (COG): a Phase III, multicenter, double-blind, placebo-controlled randomized trial. Lancet Oncol. 15(8), 894–904 (2014).
  Medline CASGoogle Scholar
• 135. Maron SB, Alpert L, Kwak HA et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastresophageal adenocarcinoma. Cancer Discov. 8(6), 696–713 (2018).
  Medline CASGoogle Scholar